-
Professor Zhang Yonghong: Two Decades of Transformation in Precision Diagnosis and Treatment of Pediatric Lymphoma in China
For many years, the treatment of pediatric lymphoma has been challenged by marked variability in therapeutic response and poor outcomes in relapsed or refractory cases. Under the leadership of Professor Zhang Yonghong, his team has driven the development of standardized and precision-based treatment strategies through long-term research and clinical innovation. In particular, they have achieved…
-
58.4-Month Follow-up Update: KEYNOTE-859 Asian Subgroup Solidifies Pembrolizumab Plus Chemotherapy as First-Line Standard for Gastric Cancer
At the recent ESMO-ASIA Congress, Professor Takayuki delivered an in-depth interpretation of the latest follow-up data from the Asian subgroup of the KEYNOTE-859 study. The presentation explored the long-term clinical value of pembrolizumab plus chemotherapy as a first-line treatment for Asian patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, providing a comprehensive look at…
-
ASH 2025 | Prof. Jeff Sharman on Mosunetuzumab and Treatment Advances Beyond R-CHOP
At ASH 2025, Prof. Jeff Sharman from the Willamette Valley Cancer Research Institute shares key clinical insights on mosunetuzumab, focusing on its safety, efficacy, and durability of response, particularly in…
-
ASH 2025 | Live Insights on Next-Generation Immunotherapies
At ASH 2025, Dr. Shannuo Li from the University of Utah, USA shares her perspective on emerging strategies for multi-target immune engagement, exploring the potential of simultaneously targeting BCMA, CD38,…
-
ASH China Voice | Professor Cai Zhen: Multidimensional Exploration and Precision Breakthroughs in Multiple Myeloma — From Mechanistic Insights to Therapeutic Innovation
At the recent Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Cai Zhen and Professor He Jingsong from The First Affiliated Hospital, Zhejiang University School of Medicine, had 12 studies accepted, comprehensively showcasing systematic investigations in multiple myeloma ranging from basic research to clinical translation. These studies focused on…
-
ASH China Voice | Professor Du Juan: First-Line BCMA/CD19 Dual-Target FasTCAR-T Redefines Outcomes for Patients with Newly Diagnosed Multiple Myeloma
Multiple myeloma is one of the most common hematologic malignancies, characterized by marked biological heterogeneity and a complex disease course. Achieving deep and durable remission at initial diagnosis is critical for improving long-term outcomes. At the recent Annual Meeting of the American Society of Hematology (ASH), Professor Du Juan’s study was selected for oral presentation,…
-
ASH Voice from China丨Professor Hu Kai: Addressing Clinical Needs and FrontiersMultiple Advances in CAR-T Cell Therapy for Relapsed/Refractory Lymphoma
The 67th Annual Meeting of the American Society of Hematology (ASH) was held from December 6 to 9, 2025, in Orlando, bringing together the latest global advances in hematology research and clinical practice. At this year’s meeting, the team led by Professor Hu Kai from Beijing Gaobo Hospital presented seven studies focusing on CAR-T cell…
-
Professor Zhisong He: Advances and Unresolved Challenges in the Treatment of Non–Muscle-Invasive Bladder Cancer
UroStream : You presented a keynote lecture entitled “Advances and Challenges in NMIBC Treatment.” Could you first outline the current main treatment paradigms for NMIBC and their limitations? Professor Zhisong…
Connecting Medical Expertise through Media